Outlook: The profit problem in antibiotic R&D

Nature Reviews Drug Discovery

Volumn 4, Issue 11, 2005, Pages 887-891

  Nathan, Carl ^a,b   Goldberg, Frederick M ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c Saltchuk Resources Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ENROFLOXACIN; VACCINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CAMPYLOBACTER; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG USE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HUMAN; LAW; LAW SUIT; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

ANTI-BACTERIAL AGENTS; BIOMEDICAL RESEARCH; DRUG DESIGN; DRUG INDUSTRY; GOVERNMENT AGENCIES; MARKETING; RESEARCH SUPPORT; UNITED STATES;

EID: 27844473756     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1878     Document Type: Article

References (8)

1. Wenzel, R. P. The antibiotic pipeline - challenges, costs, and values. N. Engl. J. Med. 351, 523-526 (2004).
2. Nathan, C. Antibiotics at the crossroads. Nature 431, 899-902 (2004).
3. Levy, S. B. & Marshall, B. Antibacterial resistance worldwide: Causes, challenges and responses. Nature Med. 10, S122-S129 (2004).
4. Projan, S. J. Why is big pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427-430 (2003).
5. Infectious Diseases Society of America. Bad bugs, no drugs: As antibiotic discovery stagnates, a public health crisis brews [online], (2004).
6. Anonymous. Citing human threat, U.S. bans a poultry drug. New York Times A17 (29 July 2005).
7. Kremer, M. & Glennerster, R. Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases (Princeton Univ. Press, Princeton, 2004).
8. Center for Responsive Politics. Pharmaceuticals/health products: long-term contribution trends [online], (2005).